Abstracts tagged "cytokines and rheumatoid arthritis (RA)"

Abstract Number: 880 • 2018 ACR/ARHP Annual Meeting
Serum Cytokine and Chemokine Concentrations Predict Incident Cancer in US Veterans with Rheumatoid Arthritis
Bryant R. England¹, Harlan Sayles², Punyasha Roul², Apar Ganti³, Jeremy Sokolove⁴, William H. Robinson⁵, Grant W. Cannon⁶, Brian Sauer⁷, Joshua Baker⁸, Geoffrey M. Thiele² and Ted R. Mikuls⁹, ¹Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Division of Immunology and Rheumatology, Stanford University Medical Center, Mountain View, CA, ⁵Stanford University, Palo Alto, CA, ⁶Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁷Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁸Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ⁹VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The immune system plays a critical protective role in cancer (CA) development. Perturbations in immune signaling, including cytokine dysregulation, may disrupt this homeostatic balance.…
Abstract Number: 1017 • 2018 ACR/ARHP Annual Meeting
Autoantigen Pentraxin-3 Is an Inflammatory Cytokine Storms Suppressor By Switching Monocytes Pyroptosis to Apoptosis in a Complement-Dependent Manner in Rheumatoid Arthritis
Xuan Zhang¹ and Xunyao Wu², ¹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Peking Union Medical College Hospital, beijing, China
Background/Purpose: A delayed diagnoses and therapy of ACPA (Anti cyclic citrullinated peptide antibody)-negative RA patients might be associated with effective serum biomarkers in clinic. Methods:…
Abstract Number: 1473 • 2018 ACR/ARHP Annual Meeting
Performance of the Meso Scale Multiplex Platform in the Assessment of Serum Cytokines / Chemokines in Rheumatoid Arthritis
Peter M. Maloley¹, Bryant R. England², Harlan Sayles¹, Geoffrey M. Thiele¹, Michael J. Duryee³, Jeffrey Payne⁴ and Ted R. Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, ⁵Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cytokines and chemokines (CK) are central to RA pathogenesis, a fact underscored by the emergence of multiplex immunoassays for quantifying CK values in both…
Abstract Number: 2879 • 2018 ACR/ARHP Annual Meeting
Plasma IL-23 and IL-25 Predict Response to Anti-TNF-α Therapy in Rheumatoid Arthritis
Niamh Fanning¹, Melanie J Millier², John Highton², Christopher Frampton³, Paul A Hessian² and Lisa K. Stamp³, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Department of Medicine, University of Otago, Dunedin, New Zealand, ³University of Otago, Christchurch, New Zealand
Background/Purpose: TNF-α inhibitors are among the most widely used biological-DMARDs in rheumatoid arthritis (RA). Means to predict response would allow for a more effective, targeted…
Abstract Number: 2425 • 2017 ACR/ARHP Annual Meeting
Decline in CD8+IFNγ+ Subset but Rise in CD8+IL17+ on Methotrexate Treatment in Rheumatoid Arthritis
Amit Sandhu¹, Varun Dhir², Shabeer Ahmad¹, Prabhdeep Kaur¹, Veena Dhawan³ and Archana Bhatnagar⁴, ¹Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³Experimental Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁴Biochemistry, Panjab University, Chandigarh, India
Background/Purpose: CD8 T cells comprise 40 % of all T cells in the synovial compartment and are detectable in he preclinical stages as well. They…
Abstract Number: 2701 • 2017 ACR/ARHP Annual Meeting
TNFR2+ Regulatory T Cellssubpopulations ARE Highly Suppressive and Are Increased on Anti-TNF Treatment
Francois Santinon¹, Maxime Batignes², Benoit Salomon³, Patrice Decker², Marie-Christophe Boissier⁴, Luca Semerano⁵ and Natacha Bessis², ¹INSERM UMR 1125 University of Paris 13, Sorbonne Paris Cité, bobigny, France, ²INSERM UMR 1125 University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ³Sorbonne Universités, UPMC Université Paris 06, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France, ⁴Rheumatology Department, Assistance Publique – Hôpitaux de Paris (AP-HP), Avicenne Hospital, Bobigny, France, ⁵INSERM UMR 1125 University of Paris 13, Sorbonne Paris Cité and Assistance Publique – Hôpitaux de Paris (AP-HP), Avicenne Hospital, Rheumatology Department, France, Bobigny, France
Background/Purpose: In rheumatoid arthritis (RA), regulatory T cells (Tregs) are defective in their suppressive capacities and fail to control chronic inflammation. TNF-α is involved in…
Abstract Number: 2870 • 2017 ACR/ARHP Annual Meeting
Ex Vivo Comparison of Baricitinib, Upadacitinib, Filgotinib, and Tofacitinib for Cytokine Signaling in Human Leukocyte Subpopulations
Iain B. McInnes¹, Richard Higgs², Jonathan Lee², William L. Macias², Songqing Na², Robert A. Ortmann², Guilherme Rocha², Thomas Wehrman³, Xin Zhang², Steven H. Zuckerman² and Peter C. Taylor⁴, ¹University of Glasgow, Glasgow, United Kingdom, ²Eli Lilly and Company, Indianapolis, IN, ³Primity Bio, Fremont, CA, ⁴NDORMS, University of Oxford, Oxford, United Kingdom
Background/Purpose: Baricitinib (bari), an oral selective Janus kinase (JAK) 1/2 inhibitor, has been approved in the EU for the treatment of adults with moderately to…
Abstract Number: 22 • 2017 ACR/ARHP Annual Meeting
Bone Regulatory Cytokine Production By B Cells in Rheumatoid Arthritis Is Dependent on NF-κb Activation and Autophagy Pathways
Jason Glanzman¹, Nida Meednu¹, Victor Wang¹, Wen Sun², Lianping Xing³ and Jennifer H. Anolik¹, ¹Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Nanjing Medical University, Nanjing, China, ³Pathology & Lab Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease that often leads to joint damage, a process mediated by an imbalance between bone resorption and…
Abstract Number: 72 • 2017 ACR/ARHP Annual Meeting
The Presence of IgM Rheumatoid Factor Impede Immunodetection of Tnfa on Circulating Extracellular Vesicles Obtained from Rheumatoid Arthritis Patients
Onno J. Arntz¹, Bartijn C.H. Pieters¹, Rogier Thurlings², Peter M. van der Kraan³, F van den Hoogen² and Fons A.J. van de Loo³, ¹Experimental Rheumatology, Radboudumc, Nijmegen, Netherlands, ²Rheumatology, Radboudumc, Nijmegen, Netherlands, ³Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: Tumor-necrosis factor (TNF)-α plays a key role in the pathophysiology of rheumatoid arthritis (RA) and membrane bound TNFα is sufficient to induce arthritis in…
Abstract Number: 404 • 2017 ACR/ARHP Annual Meeting
Gut Microbiota Modify Inflammatory Arthritis through Autoantibody Generation and Mucosal Cytokines Alteration
Widian Jubair¹, Sumitra Adhikari², Nirmal Banda² and Kristine Kuhn³, ¹Rheumatology, University of Colorado, Aurora, CO, ²Division of Rheumatology, UC Denver School of Medicine, Denver, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is thought to be influenced by a combination of genetic and environmental factors. Observations of microbial dysbiosis in…
Abstract Number: 521 • 2017 ACR/ARHP Annual Meeting
Update on the Clinical Phase 1 and Phase 2 Trials Investigating the Fully Human Immunocytokine Dekavil (F8IL10) in Patients with Rheumatoid Arthritis
Mauro Galeazzi¹, Gian Domenico Sebastiani², Jürgen Wollenhaupt³, Jean Dudler⁴, Christof Specker⁵, Reinhard Voll⁶, Pascal Zufferey⁷, Piercarlo Sarzi Puttini⁸, Ombretta Viapiana⁹ and Franziska Bootz¹⁰, ¹Rheumatology, University Hospital of Siena, Siena, Italy, ²Rheumatology, San Camillo Forlanini Hospital, Roma, Italy, ³Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ⁴Rheumatology, Cantonal Hospital Fribourg, Fribourg, Switzerland, ⁵Rheumatology, St. Josef Krankenhaus, Universitätsklinikum Essen, Esssen, Germany, ⁶Clinic for Rheumatology and Clinical Immunology, Medical Center University of Freiburg, Freiburg, Germany, ⁷Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, ⁸Rheumatology, Luigi Sacco Hospital, Milan, Italy, ⁹University Hospital Verona, Verona, Italy, ¹⁰Clinical Department, Philochem AG (Philogen Group), Otelfingen, Switzerland
Background/Purpose: The antibody-based targeted pharmacodelivery of cytokines by means of immunocytokines has the potential to enhance therapeutic activity at the site of disease while sparing…
Abstract Number: 956 • 2017 ACR/ARHP Annual Meeting
Inhibition of Fucosylation in Endothelial Cells Reduces Rheumatoid Arthritis Angiogenesis
Takeo Isozaki, Airi Nishimi, Shinichiro Nishimi, Sho Ishii, Takahiro Tokunaga, Hidekazu Furuya, Kuninobu Wakabayashi and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: Glycosylation has been reported to associate with tumor invasion and metastasis. Fucosylation is involved the biological functions of adhesion molecules and growth factor receptors.…
Abstract Number: 957 • 2017 ACR/ARHP Annual Meeting
A Disintegrin and Metalloprotease 15 Is Expressed on Rheumatoid Arthritis Synovial Tissue Endothelial Cells and Mediates Angiogenesis
Shinichiro Nishimi, Takeo Isozaki, Airi Nishimi, Sho Ishii, Takahiro Tokunaga, Hidekazu Furuya, Kuninobu Wakabayashi and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: A disintegrin and metalloproteases (ADAMs) are reported that membrane-anchored glycoproteins composed of multiple distinct protein modules. ADAM-15 is one of them and is reported…
Abstract Number: 958 • 2017 ACR/ARHP Annual Meeting
Tumor Necrosis Factor-α Induces Production of Eotaxin-1/CCL11 from Fibroblast-like Synoviocyte in Rheumatoid Arthritis
Kuninobu Wakabayashi, Takeo Isozaki, Airi Nishimi, Shinichiro Nishimi, Sho Ishii, Takahiro Tokunaga, Hidekazu Furuya and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: Chemokine C-C motif ligand 11 (CCL11) also known as eotaxin-1 is a member of the CC chemokine family, which acts as a major chemoattractant…
Abstract Number: 1348 • 2017 ACR/ARHP Annual Meeting
Swollen Joint Count, but Not Inflammatory Cytokines, Differs By Frequency of Fish Consumption in a Cross-Sectional Rheumatoid Arthritis Cohort
Sara K. Tedeschi¹, Joan Bathon², Jon T. Giles³, Tzu-Chieh Lin⁴, Kazuki Yoshida⁵ and Daniel Solomon¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ³Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: Omega-3 fatty acids downregulate pro-inflammatory cytokines, thus have been of interest as adjunctive rheumatoid arthritis (RA) therapy for decades. We previously reported an inverse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.